Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

Safety and efficacy of platinum agents plus etoposide for patients with small cell lung cancer with interstitial lung disease.

Yoshida T, Yoh K, Goto K, Niho S, Umemura S, Ohmatsu H, Ohe Y.

Anticancer Res. 2013 Mar;33(3):1175-9.

PMID:
23482799
2.

Evaluation of the safety and efficacy of combination chemotherapy with vinorelbine and platinum agents for patients with non-small cell lung cancer with interstitial lung disease.

Okuda K, Hirose T, Oki Y, Murata Y, Kusumoto S, Sugiyama T, Ishida H, Shirai T, Nakashima M, Yamaoka T, Ohnishi T, Ohmori T.

Anticancer Res. 2012 Dec;32(12):5475-80.

PMID:
23225454
3.

Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: results from the SALUTE trial.

Spigel DR, Townley PM, Waterhouse DM, Fang L, Adiguzel I, Huang JE, Karlin DA, Faoro L, Scappaticci FA, Socinski MA.

J Clin Oncol. 2011 Jun 1;29(16):2215-22. doi: 10.1200/JCO.2010.29.3423.

PMID:
21502556
4.

Outcomes of Platinum-Sensitive Small-Cell Lung Cancer Patients Treated With Platinum/Etoposide Rechallenge: A Multi-Institutional Retrospective Analysis.

Genestreti G, Tiseo M, Kenmotsu H, Kazushige W, Di Battista M, Cavallo G, Carloni F, Bongiovanni A, Burgio MA, Casanova C, Metro G, Scarpi E, Korkmaz T, Selcuk S, Roopa K, Califano R.

Clin Lung Cancer. 2015 Nov;16(6):e223-8. doi: 10.1016/j.cllc.2015.04.006.

PMID:
25983005
5.

Prognostic significance of preexisting interstitial lung disease in Japanese patients with small-cell lung cancer.

Togashi Y, Masago K, Handa T, Tanizawa K, Okuda C, Sakamori Y, Nagai H, Kim YH, Mishima M.

Clin Lung Cancer. 2012 Jul;13(4):304-11. doi: 10.1016/j.cllc.2011.11.001.

PMID:
22169479
6.

Topotecan-carboplatin-etoposide combination as 1st line treatment in patients with small cell lung cancer.

Zarogoulidis K, Mylonaki E, Kakavelas P, Zarogoulidis P, Tsiouda T, Rapti E, Lithoxopoulou H, Zarogoulidou V, Kontakiotis T; Hellenic Pulmonary Oncology Study Group (HE.P.O.G.)..

Lung Cancer. 2009 Nov;66(2):226-30. doi: 10.1016/j.lungcan.2009.02.003.

PMID:
19321222
7.

[Evaluation of chemotherapy, especially combined therapy with Carboplatin Plus Etoposide(CE), in patients aged > or =80 years old with extensive-disease small-cell lung cancer].

Tamiya A, Tsuya A, Nakamura Y, Kaira K, Naitou T, Murakami H, Takahashi T, Endo M, Yamamoto N.

Gan To Kagaku Ryoho. 2010 Jun;37(6):1041-4. Japanese.

PMID:
20567104
8.
9.

Addition of darbepoetin alfa to dose-dense chemotherapy: results from a randomized phase II trial in small-cell lung cancer patients receiving carboplatin plus etoposide.

Nagel S, Kellner O, Engel-Riedel W, Guetz S, Schumann C, Gieseler F, Schuette W.

Clin Lung Cancer. 2011 Jan;12(1):62-9. doi: 10.3816/CLC.2011.n.009.

PMID:
21273182
11.

Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer.

Socinski MA, Smit EF, Lorigan P, Konduri K, Reck M, Szczesna A, Blakely J, Serwatowski P, Karaseva NA, Ciuleanu T, Jassem J, Dediu M, Hong S, Visseren-Grul C, Hanauske AR, Obasaju CK, Guba SC, Thatcher N.

J Clin Oncol. 2009 Oct 1;27(28):4787-92. doi: 10.1200/JCO.2009.23.1548.

PMID:
19720897
12.

Combination of three cytotoxic agents in small-cell lung cancer.

Stathopoulos GP, Trafalis D, Dimitroulis J, Kosmas Ch, Stathopoulos J, Tsavdaridis D.

Cancer Chemother Pharmacol. 2013 Feb;71(2):413-8. doi: 10.1007/s00280-012-2022-8.

13.

Outcomes of small-cell lung cancer patients treated with second-line chemotherapy: a multi-institutional retrospective analysis.

Garassino MC, Torri V, Michetti G, Lo Dico M, La Verde N, Aglione S, Mancuso A, Gallerani E, Galetta D, Martelli O, Collovà E, Fatigoni S, Ghidini A, Saggia C, Bareggi C, Rossi A, Farina G, Thatcher N, Blackhall F, Lorigan P, Califano R.

Lung Cancer. 2011 Jun;72(3):378-83. doi: 10.1016/j.lungcan.2010.09.009.

PMID:
20950888
14.

Second-line Chemotherapy for Patients with Small Cell Lung Cancer and Interstitial Lung Disease.

Fujimoto D, Shimizu R, Kato R, Sato Y, Kogo M, Ito J, Teraoka S, Otoshi T, Nagata K, Nakagawa A, Otsuka K, Katakami N, Tomii K.

Anticancer Res. 2015 Nov;35(11):6261-6.

PMID:
26504060
15.

Optimization of small-cell lung cancer chemotherapy with heparin: a comprehensive retrospective study of 239 patients treated in a single specialized center.

Lebeau B, Baud M, Masanes MJ, Febvre M, Mokhtari T, Chouaïd C.

Chemotherapy. 2011;57(3):253-8. doi: 10.1159/000328014.

PMID:
21654168
17.

Effect of platinum-based chemotherapy for non-small cell lung cancer patients with interstitial lung disease.

Kenmotsu H, Naito T, Mori K, Ko R, Ono A, Wakuda K, Imai H, Taira T, Murakami H, Endo M, Takahashi T.

Cancer Chemother Pharmacol. 2015 Mar;75(3):521-6. doi: 10.1007/s00280-014-2670-y.

PMID:
25563718
18.

Etoposide pharmacokinetics and survival in patients with small cell lung cancer: a multicentre study.

You B, Tranchand B, Girard P, Falandry C, Ribba B, Chabaud S, Souquet PJ, Court-Fortune I, Trillet-Lenoir V, Fournel C, Tod M, Freyer G.

Lung Cancer. 2008 Nov;62(2):261-72. doi: 10.1016/j.lungcan.2008.03.008.

PMID:
18442869
19.

Phase II trial of amrubicin and carboplatin in patients with sensitive or refractory relapsed small-cell lung cancer.

Hirose T, Nakashima M, Shirai T, Kusumoto S, Sugiyama T, Yamaoka T, Okuda K, Ohnishi T, Ohmori T, Adachi M.

Lung Cancer. 2011 Sep;73(3):345-50. doi: 10.1016/j.lungcan.2010.12.015.

PMID:
21277039
20.

Chemotherapy for small cell lung carcinoma: the Greenlane Hospital experience 1993-1995.

Lee YC, McCrystal MR, Christmas TI.

N Z Med J. 1998 Nov 27;111(1078):451-2, 453-4.

PMID:
9891564

Supplemental Content

Support Center